2nd round audit of skeletal surveys in patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
Poster Aug 29, 2014
Dr Ganesh Retnasingam, Dr Laura Day and Dr Yvette Griffin
To ensure British Journal of Haematology guidelines are being followed by the haematologists at University Hospitals of Leicester and no unnecessary requests for skeletal surveys in MGUS as per agreed action plan following results from 1st round audit.
Results of 1st round audit from 16/10/2006 to 16/12/2011 showed 14% of 88 MGUS patients had a skeletal survey when not indicated. This is because they had a paraprotein <10g/l and no other risk factors.
We retrospectively reviewed consecutive patients from the myeloma MDT database, newly diagnosed with MGUS, between May 2013 to May 2014.
From ilab we obtained paraprotein type/level, serum kappa/lambda ratio, renal function, full blood count, B2 microglobulin, serum calcium, albumin, urine Bence-Jones Protein. If any of these were abnormal they were considered risk factors for progression to myeloma.
24 patients: 8 male, 16 female. Average age 72, age range 49 to 92. Only 1 patient had skeletal survey when not indicated with a serum paraprotein level of 2.2g/l and no risk factors.
MHV68 Infection in a Novel rag2 F62L/F62L Mouse Model Based on a Patient with CID-G/AI PhenotypePoster
MHV-68 infection in our rag2 mouse model induced increased antibody responses to virus and self and inflammatory disease in end organs. Major mechanism of inflammatory infiltrates and autoantibody generation is yet to be determinedREAD MORE
Rare Diagnosis of Malignant Mesothelioma in a Young Patient with Rheumatoid ArthritisPoster
This is a rare presentation of malignant pleural mesothelioma in a young female patient with rheumatoid arthritis and no known asbestos exposure.READ MORE
Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy TargetsPoster
The human immune system is comprised of a complex network of immune checkpoint receptors that are promising new immunotherapy targets for the treatment of a variety of diseases including cancer and autoimmune-mediated disorders.READ MORE